The redox reaction interconverting ketones and alcohols is mainly catalyzed by enzymes belonging to two superfamilies, the aldo-keto reductases (AKR) and short-chain dehydrogenases/reductases (SDR).
Currently, more than 3000 SDRs are known while 121 AKRs are listed in the AKR-homepage (http://www.med.upenn.edu/akr/), 13 of which are occurring in man (Bohren et al., 1989; Penning, 2004) . Despite their overall structural similarity, AKR enzymes show considerable diversity in terms of substrate specificity, acting on numerous aliphatic and aromatic aldehydes and ketones, steroids, prostaglandins, sugars and xenobiotics. AKRs can be considered as enzymes participating in phase I drug metabolism and accelerating the elimination of potential toxicants.
Carbonyl group reduction provides the hydroxy group necessary for conjugation reactions and the resulting hydrophilic molecules can be excreted via bile and/or urine. AKR1B10 belongs to the aldose reductases (AKR1B subfamily) and was discovered as an enzyme being overexpressed in human liver cancers and in the search of aldose reductase homologues (Jez et al., 1997; Cao et al., 1998; Scuric et al., 1998; Hyndman and Flynn, 1998) . It shares 70 % identity with human aldose reductase AKR1B1. Expression levels are high in human small intestine and adrenal gland and lower in all other tissues tested so far (Cao et al., 1998; Hyndman and Flynn, 1998) . Recent observations suggest that its physiological substrates are retinal isomers (Crosas et al. 2003) . In previous studies, we purified oxidoreductases from human liver cytosol catalyzing redox reactions of various substrates (Breyer-Pfaff and Nill, 2000; Atalla et al., 2000) . Based on this procedure we could now purify AKR1B10 in an active state and identify its nature by ESI-MS/MS analysis. To investigate the role of this comparatively new member of the AKR family in the carbonyl reduction of xenobiotics, we overexpressed AKR1B10 in E. coli and used both, the native and recombinant enzymes, to characterize enzymatic properties and assess kinetic parameters. As AKR1B10 is overexpressed in lung cancer (Hyndman and Flynn, 1998; Penning, 2005; ) , we checked the purified enzyme for its ability to accept NNK as substrate. There is strong evidence that NNK plays a major role in the causation of lung cancer in smokers (Hecht, 1998) . In addition, the two anti-cancer drugs daunorubicin, which is among others used in the treatment of lung cancer, and oracin, a potential cytostatic drug for oral use which is This article has not been copyedited and formatted. The final version may differ from this version. at present in phase II of clinical trials, were tested for carbonyl reduction. All of the above-mentioned compounds were converted by AKR1B10 to the corresponding alcohols. We also present data for carbonyl reduction of the opioid receptor antagonist naltrexone and the antiemetic 5-HT 3 receptor antagonist dolasetron which are efficiently reduced in vivo (Gonzalez and Brogden, 1988; Dow and Berg, 1995) . While the reduction of naltrexone proceeded slowly, AKR1B10 was among the most efficient reductases of dolasetron characterized so far (Breyer-Pfaff and Nill, 2004) .
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Materials and Methods
The following columns and materials used for protein isolation were purchased from Pharmacia (Freiburg, Germany): Superdex™ 75 column, 1 ml HiTrap™ Chelating column, Sephadex G-100, Q Sepharose, CM Sepharose, Polybuffer Exchanger PBE 94, and Polybuffer 74. Hydroxyapatite Bio-Gel HTP was from Bio-Rad, a 50-ml ultrafiltration chamber and filters YM10 from Amicon, (S)-(+)-and (R)-(-)-1-indanol, glyceraldehyde, NADPH and glucose-6-phosphate from Sigma-Aldrich. The molecular weight standards were from Sigma-Aldrich and Fermentas. NADP-tetrasodium salt was purchased from AppliChem (Darmstadt, Germany), glucose-6-phosphate dehydrogenase from yeast, grade I, ca. 350 U/mg, from Roche Diagnostics (Mannheim, Germany). NNK was supplied from Campro Scientific (Emmerich, Germany). Naltrexone hydrochloride was kindly provided by DuPont Pharma (Bad Homburg, Germany) and dolasetron mesilate hydrate by Hoechst Marion Roussel (Bad Soden, Germany). Reduced dolasetron was prepared according to Dow and Berg (1995) as described (Breyer-Pfaff and Nill 2004) . Oracin and dihydrooracin were gifts from the Research Institute for Pharmacy and Biochemistry (Prague, Czech Republic). Daunorubicin was from Rhône-Poulenc, Cologne, Germany, reduced daunorubicin was obtained from Pharmacia-Farmitalia Carlo Erba (Milan, Italy). Pfu-polymerase and T4 ligase were purchased from Fermentas and restriction enzymes from New England Biolabs. Bacterial strains used in this study and the pQE-60 vector were from Qiagen (Hilden, Germany). The human liver cDNA library Uni-ZAp ® XR was from Stratagene. Primers were prepared by MWG (Ebersberg, Germany). Ampicillin and kanamycin were from AGS (Heidelberg, Germany).
Enzyme isolation and purification. Human liver samples were provided by the Department of Surgery, University of Tuebingen. They were either excess normal tissue removed on partial hepatectomy for liver metastases or materials excluded from transplantation for medical reasons. The samples were stored at -80°C for 0.5 to 7 years. Homogenates were prepared with 4 volumes of homogenization buffer (250 mM sucrose, 20 mM Tris-HCl, 5 mM EDTA, adjusted to pH 7.4 at 37°C) and cytosol was obtained by differential centrifugation. The enzyme isolation was a modification This article has not been copyedited and formatted. The final version may differ from this version. Breyer-Pfaff and Nill, 2000) of the method of Hara et al. (1990) ;. Cytosol from 5-7 g of liver was concentrated to half its volume by ultrafiltration and fractionated on a 2.5 × 100 cm column with Sephadex G-100 using 25 mM Tris-HCl pH 7.4. Fractions testing positive for oxidoreductase activity were concentrated with the medium being changed to buffer A (400 ml 6.25 mM Tris + 0.625 mM EDTA adjusted to pH 8.0 with HCl and 100 ml glycerol, with 2-mercaptoethanol added to 5 mM before use). In all further purification steps, 2-mercaptoethanol was added to buffers to a concentration of 5 mM prior to use. The elution rate was 1 ml/min except on chromatofocusing, and fractions of 5 ml or 2.5 ml were tested for enzymatic activity, then combined, concentrated and stored in buffer A at -80°C. 
Gel permeation chromatography. Gel filtration was performed on an Amersham Pharmacia
ÄKTA FPLC system using a Pharmacia Superdex™ 75 column. The column was equilibrated with a buffer containing 20 mM Tris-HCl pH 7.4, 200 mM NaCl, 0.2 mM 2-mercaptoethanol, and 10%
glycerol. Elution of 12 µg of native AKR1B10 was detected by recording the absorption at 280 nm. The standard curve was generated by using the low molecular weight calibration kit from AmershamPharmacia.
This article has not been copyedited and formatted. The final version may differ from this version. Cloning and expression of AKR1B10 in E. coli. The coding sequence of AKR1B10 (NCBI Reference Sequence accession number: NM_020299) was amplified from a human liver cDNA-library (Stratagene) by PCR using primers of the following sequence: forward primer, ATGGCCACGTTTGTGGAG; reverse primer, CCTCAATATTCTGCATCGAAGG. PCR was performed with Pfu-Polymerase in 30 cycles with an annealing temperature of 52°C. In a second PCR reaction, BgI II restriction sites were added using appropriate primers and the resulting construct was ligated into the pQE-70 (Qiagen) vector such that the protein was translated in frame from the vector's translation start site resulting in a protein containing a C-terminal His-tag. For expression of AKR1B10
protein, SG13009 cells (Qiagen) were transformed with the expression plasmid and a 200 ml culture containing ampicillin (100 µg/ml) and kanamycin (25 µg/ml) was grown to OD 600 = 0.6 at 37 °C.
Expression was induced by supplementing the culture medium with 1 mM isopropyl-1-thiogalactopyranoside. Cells were harvested after 3 hours by centrifugation (6000 g, 10 min) and resuspended in 20 ml of Tris buffer (20 mM Tris⋅HCl, pH 7.4, 100 mM NaCl, 10 mM imidazole) before lysation in a French-pressure cell. The resulting suspension was centrifuged for 1 hour at 100000 g at 4°C and the supernatant either stored at -80°C or directly used for Ni-affinity chromatography.
Purification of recombinant AKR1B10. Purification of AKR1B10 was achieved by FPLC (ÄKTA-Purifier, Amersham-Pharmacia) on a 1 ml Ni 2+ HisTrap-FF column. A linear gradient of 10 mM -500 mM imidazole in 20 mM NaH 2 PO 4 , 100 mM NaCl, 10% glycerol, pH 7.4 was used.
AKR1B10 was eluted from the column at an imidazole concentration of about 200 mM. Proteincontaining fractions were analyzed by SDS-PAGE. Samples containing pure AKR1B10 were pooled and 5× concentrated by ultrafiltration, thereby exchanging the elution buffer with 10 mM Tris⋅HCl, pH 8.0, 0.5 mM EDTA, 20% glycerol, 5 mM 2-mercaptoethanol. Purified protein was stored in this buffer at -80°C until further use.
This article has not been copyedited and formatted. The final version may differ from this version. Immunoblotting. Antisera against full length AKR1B10 were prepared by Eurogentec, Belgium, by using recombinant protein produced in our lab. Electroblotting was performed in a semidry blotting system. Proteins were transferred on a nitrocellulose membrane, and antigen-antibody complexes were visualized by chemoluminescence (ECL plus detection kit, Amersham-Biosciences). Primary antibodies were diluted 1/1000; the secondary antibody (peroxidase-conjugated swine anti-rabbit immunoglobulin, DakoCytomation, Denmark) was used in a 1/10000 dilution. Enzyme kinetics. Dolasetron reduction kinetics were determined by incubating 0.01 -0.3 mM substrate with 1 µg of purified AKR1B10 in 0.36 ml of the above buffer containing 0.2 mM NADP + , 2 mM glucose-6-phosphate and 1 U/ml glucose-6-phosphate dehydrogenase for NADPH generation.
After 20 min at 37°C, the reaction was stopped by adding 40 µl of 2 M perchloric acid and cooling on ice. Reduced dolasetron was analysed in the supernatant by HPLC (Breyer-Pfaff and Nill, 2004) . In analogous fashion, naltrexone reduction was checked in a few samples. NNK (0.05 -1.5 mM), oracin (0.02 -0.75 mM) and daunorubicin (0.15 -2 mM) reduction kinetics were assayed with 2.72, 1.36 and 0.68 µg of purified AKR1B10, respectively, in a total volume of 0.1 ml in 0.1 M sodium phosphate buffer, pH 7.4 and an NADPH-generating system (final concentrations: NADP + , 3 mM; glucose 6-phosphate, 20 mM; glucose-6-phosphate dehydrogenase, 1.8 units / 0.1 ml; MgCl 2 , 10 mM). Incubation times were 60, 30 and 10 min, respectively. Increase of product concentration was linear during the This article has not been copyedited and formatted. The final version may differ from this version. given periods of time. Reactions were stopped by the addition of 40 µl 30% ammonia and cooling on ice. The mixtures were extracted twice with 300 µl of ethylacetate (thrice in the case of daunorubicin) and the combined organic phases were evaporated under vacuum. The residue was dissolved in the respective mobile phase and analyzed by HPLC as described (Wsol et al., 1996; . For daunorubicinol detection, a modified method of Fogli et al. (Fogli et al., 1999) This article has not been copyedited and formatted. The final version may differ from this version. 
Results
In the search for enzymes participating in the reduction of xenobiotic ketones, a purification scheme was developed which led to the simultaneous purification of the three aldo-keto reductases AKR1C1, -1C2, -1C4 and the short-chain dehydrogenase carbonyl reductase (Breyer-Pfaff and Nill, 2000) .
Monitoring (S)-1-indanol oxidation activity led to the isolation of an additional enzyme which we could now unequivocally identify as AKR1B10 by ESI-MS/MS analysis ( Table 1 ). The purified protein proved to be homogeneous on SDS-PAGE. The estimated molecular mass corresponded to that of the primary structure deduced from the cDNA sequence and was the same as that of AKR1C1 and AKR1C2 (34 -36 kDa, Fig. 1A) . A molecular mass of 35 kDa for AKR1B10 was also found by sizeexclusion chromatography (Fig. 2) .
The coding sequence of human AKR1B10 was obtained by PCR from a human liver cDNA-library.
After ligation into an expression vector, the protein was overexpressed in E. coli cells and purified in an active state by metal chelate chromatography (Fig. 1B) . The purified recombinant enzyme was soluble and could be concentrated to at least 16 mg/ml without precipitation.
Western blot of human liver cytosol probed with antibodies raised against recombinant AKR1B10
showed the presence of the enzyme in only two out of five livers (Fig. 3) . This indicates interindividual variation in the expression of AKR1B10 in human tissues.
The native and recombinant enzyme preparations displayed different kinetic properties, as shown for example for indanol oxidation (Fig. 4C) . In all cases the catalytic efficiency of the native enzyme was higher than that of its recombinant counterpart (Table 3) . Incubation of AKR1B10 with an NADPHregenerating system and the substrates listed in Tables 2 and 3 yielded the corresponding alcohols which were detected and quantified by HPLC. In the case of 1-indanol oxidation, the linear increase in absorbance at 339 nm was monitored, corresponding to the conversion of the cofactor NADP + to NADPH. AKR1B10 rapidly oxidized (S)-1-indanol, while (R)-1-indanol was oxidized at a 10-fold lower rate ( 13 exception of those for daunorubicin. Carbonyl reduction of daunorubicin was better fitted by the Hillequation with a Hill-coefficient of 1.5 (Fig. 4) . With oracin some substrate inhibition was observed. K m values were in the micromolar range for dolasetron and in the low millimolar range for the other compounds tested (Table 3) . k cat /K m values were highest for dolasetron and indanol (>100 mM -1 min -1 ) and much lower for NNK, daunorubicin and oracin (around 1 mM -1 min -1 , Table 3 ).
Experiments with common oxidoreductase inhibitors revealed a low potential of barbital and some antiinflammatory drugs and the most potent inhibition with lithocholic acid (Table 4 ).
Discussion
A modification of the original purification scheme of Hara et al. (1990) consisting of several chromatographic steps allowed for the simultaneous isolation of the three aldo-keto reductases AKR1C1, -1C2, -1C4 and the short-chain dehydrogenase/reductase carbonyl reductase from human liver cytosol (Breyer-Pfaff and Nill, 2000) . An additional fraction could be isolated irregularly and shown to contain a protein with (S)-1-indanol oxidizing activity. This protein was now identified by ESI-MS/MS as the aldo-keto reductase AKR1B10. This is the first time that this relatively new member of the aldo-keto reductase superfamily has been purified from human tissue in its native state.
AKR1B10 mRNA levels were reported to be high in small intestine, colon and adrenal gland, but only moderate amounts were found in liver (Cao et al., 1998; Hyndman and Flynn, 1998) . This is in accordance with the occasional failure to detect a peak of enzymatic activity when cytosol of different livers was subjected to the purification procedure. Interindividual variability in AKR1B10 expression was also shown in the present study by Western blot analysis, where no AKR1B10 protein was detected in three out of five human livers tested. To obtain a larger enzyme quantity, we cloned AKR1B10 in bacteria and isolated the recombinant protein by metal chelate chromatography. Native and recombinant enzyme were not identical regarding their kinetic parameters. Catalytic efficiencies of the native enzyme were 1.6 to 20 times higher compared to the recombinant form depending on the substrate. At the moment we cannot tell if this loss of activity (Table 3) is due to adverse effects of the additional amino acids derived from the cloning procedure, sub-optimal purification conditions or a lack of posttranslational modifications.
In order to assess the importance of AKR1B10 in the detoxification of xenobiotics, we determined the kinetic parameters of several carbonyl-group containing compounds. Recently, it was shown that AKR1B10 is a very efficient retinal reductase (Crosas et al., 2003) . Published data indicate that the preferred substrates for this enzyme are aldehydes (Cao et al., 1998; Crosas et al., 2003) , but both the native and the recombinant enzyme reduced the carbonyl group of various ketones (Table 3) . In
This article has not been copyedited and formatted. The final version may differ from this version. Breyer-Pfaff and Nill, 2000) . AKR1B10 exhibited an about 10-fold lower activity towards (R)-1-indanol (Table 2 ). The opiate receptor antagonist naltrexone was reduced by AKR1B10 very slowly as it was also found for AKR1C1 and AKR1C2 (Breyer-Pfaff and Nill, 2004) .
In contrast, AKR1B10 is one of the most active reductases towards dolasetron, a 5-HT 3 receptor antagonist used as an antiemetic drug which is efficiently reduced to its corresponding alcohol in vivo.
The k cat /K m value exceeded 100 mM -1 min -1 in three independent kinetic experiments ( Table 3 ). The enzymatic efficiency is at least as high as that of AKR1C1 and superior to that of AKR1C2 in dolasetron reduction (Breyer-Pfaff and Nill, 2004) . Reduced dolasetron is the active metabolite with a half-life (t ½ ) of 7-8 hours, whereas a t ½ of 0.13-0.24 hours is observed for the parent carbonyl compound (Gan, 2005 and references cited therein). Carbonyl reductase was held responsible for this rapid elimination, because conversion to the alcohol also took place in whole blood (Dow and Berg, 1995) . In view of its widespread tissue distribution (Wirth and Wermuth, 1992) , carbonyl reductase may in fact have a role, but its k cat /K m value in dolasetron reduction is only about one-third that of AKR1B10 and AKR1C1 (Breyer-Pfaff and Nill, 2004) . Participation of AKR1B10 in first-pass reduction of dolasetron may be of importance if the enzyme is highly expressed in human small intestine as reported by Cao et al. (1998) and as reflected by its original name "human small intestine reductase" (Hyndman and Flynn, 1998) . While the reduction of dolasetron is the prerequisite for its binding to the receptor and the resulting antiemetic effect, the reduction of carbonyl groups in cytostatic drugs often leads to their inactivation. We found that the anthracycline derivative daunorubicin and the novel anticancer drug oracin, which is currently in phase II of clinical trial, both were substrates for AKR1B10 albeit both were reduced with much lower enzymatic efficiency than dolasetron (Table 3) .
Surprisingly, daunorubicin reduction kinetics showed no Michaelis-Menten hyperbola but a sigmoidal 16 exclusion chromatography with the native enzyme revealed the expected molecular mass of the monomer (found, 35 kDa; calculated, 36 kDa; Fig. 2 ). Although some multimeric aldo-keto reductases are known, most members of this superfamily are monomers. Daunorubicin is mainly reduced in the cytosol by carbonyl reductase (k cat /K m = 64 mM -1 min -1 ) and to a lesser extent by AKR1C2 and AKR1A1 (previously designated as dihydrodiol dehydrogenase 2, DD2, and aldehyde reductase, ALR, respectively, in Ohara et al. (1995) . In comparison, the catalytic efficiencies of AKR1B10 for daunorubicin (k cat /K m = 1.3 mM -1 min -1 ) and oracin (k cat /K m = 0.43 mM -1 min -1 ) are low. As detailed above, AKR1B10 expression is low or absent in normal liver. On the other hand, it was easily detectable in all five hepatocellular carcinoma tissues tested, while mRNA levels in non-tumor samples were minimal (Scuric et al., 1998) . Analogously, no or low AKR1B10 expression was found in human lung (Cao et al., 1998; Hyndman and Flynn, 1998) , but recently, Fukumoto et al. reported on the overexpression of AKR1B10 in smokers' non-small cell lung carcinomas and suggested it as a diagnostic marker (Fukumoto et al., 2005; Penning, 2005) . As daunorubicin is used in the treatment of this disease, its carbonyl reduction (i.e. deactivation) by AKR1B10 may become a critical determinant in chemotherapy (Soldan et al., 1999; Ax et al., 2000; Lee et al., 2001 ).
The overexpression of AKR1B10 in squamous cell carcinoma of the lung raises the question if inhibition of this enzyme might be beneficial for patients, as the physiological role of AKR1B10 is not yet fully understood. Our results show that, on the one hand, AKR1B10 may contribute to drug resistance in cancer chemotherapy. On the other hand, one of the most potent lung carcinogens in tobacco smoke, NNK, is also reduced to the corresponding alcohol NNAL by this enzyme. This reduction constitutes the first step in the major detoxification pathway of NNK in humans and can be followed by conjugation with glucuronic acid. In human lung and liver cytosol, mostly aldo-keto reductases of the AKR1C family and carbonyl reductase of the SDR superfamily contribute to the reduction of NNK (Atalla et al., 2000; . In cancer tissues, where AKR1B10 may obviously be overexpressed manifold, the contribution of individual enzymes to NNK reduction has yet to be determined.
This article has not been copyedited and formatted. The final version may differ from this version. In conclusion, we purified AKR1B10 from human liver in an active state and cloned it from a cDNA library. The enzyme proved to be an efficient reductase of the antiemetic pro-drug dolasetron to the corresponding alcohol, a high-affinity 5-HT 3 receptor blocker. Two anti-cancer drugs, daunorubicin and oracin, and the tobacco-specific carcinogen NNK were found to be substrates of the enzyme although with low catalytic efficiency. In non-cancerous human lung tissue AKR1B10 mRNA is rarely found and expression levels of AKR1B10 in human liver are low and show high interindividual variability as revealed by Western blot analysis. Since AKR1B10 is overexpressed in human non-small cell lung carcinoma and human hepatocellular carcinoma, it may become an important factor in drug resistance against carbonyl-group bearing anti-tumor drugs in these tissues.
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